Trial Profile

A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pasireotide (Primary) ; Octreotide
Indications Acromegaly
Focus Registrational; Therapeutic Use
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

15 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
31 Mar 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database.
04 Dec 2015 Planned End Date changed from 1 Oct 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com